Julien De Greef, Jean Cyr Yombi, Anne Vincent, Bernard Vandercam, Philippe de Timary, Lidvine Boland, Magali Philippeau, Nadtha Panin, Laure Elens, Vincent Haufroid, Leïla Belkhir
{"title":"多替格拉韦与神经精神不良事件的风险：一项药物遗传学研究","authors":"Julien De Greef, Jean Cyr Yombi, Anne Vincent, Bernard Vandercam, Philippe de Timary, Lidvine Boland, Magali Philippeau, Nadtha Panin, Laure Elens, Vincent Haufroid, Leïla Belkhir","doi":"10.1093/infdis/jiaf098","DOIUrl":null,"url":null,"abstract":"Dolutegravir treatment can lead to neuropsychiatric adverse events (NPAE). This study assessed the association between NPAE and polymorphisms in dolutegravir-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued dolutegravir due to NPAE were compared to 98 patients tolerating dolutegravir. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C>T was independently associated with a reduced risk of NPAE-related dolutegravir discontinuation (odds ratio of 0.36 [95% confidence interval, .15–.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control-group participants.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study\",\"authors\":\"Julien De Greef, Jean Cyr Yombi, Anne Vincent, Bernard Vandercam, Philippe de Timary, Lidvine Boland, Magali Philippeau, Nadtha Panin, Laure Elens, Vincent Haufroid, Leïla Belkhir\",\"doi\":\"10.1093/infdis/jiaf098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dolutegravir treatment can lead to neuropsychiatric adverse events (NPAE). This study assessed the association between NPAE and polymorphisms in dolutegravir-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued dolutegravir due to NPAE were compared to 98 patients tolerating dolutegravir. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C>T was independently associated with a reduced risk of NPAE-related dolutegravir discontinuation (odds ratio of 0.36 [95% confidence interval, .15–.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control-group participants.\",\"PeriodicalId\":501010,\"journal\":{\"name\":\"The Journal of Infectious Diseases\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf098\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study
Dolutegravir treatment can lead to neuropsychiatric adverse events (NPAE). This study assessed the association between NPAE and polymorphisms in dolutegravir-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued dolutegravir due to NPAE were compared to 98 patients tolerating dolutegravir. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C>T was independently associated with a reduced risk of NPAE-related dolutegravir discontinuation (odds ratio of 0.36 [95% confidence interval, .15–.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control-group participants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
